Metabolic Side-effects for Second-generation Antipsychotics

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

241 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-11-30

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Second-generation antipsychotics (SGAs), including clozapine, are commonly used nowadays as treatment for psychosis. There are increasing concerns about their related metabolic side-effects over weight gain, risks to cause glucose intolerance and hyperlipidemia, and a specific condition known as metabolic syndrome. All these side-effects might be associated with the increased risk of cardiovascular diseases and diabetes mellitus.

This study is to analyze the simple physical measurements (weight and height) and venous blood tests (for fasting blood glucose and lipid) results collected routinely since 2008 (recommended by the local hospital authority as a territory-wide "SGAs Monitoring Program") from those outpatients receiving SGAs (amisulpride, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone and ziprasidone) and/or clozapine, at a local psychiatric outpatient clinic in Hong Kong. The investigators hypothesized that there should be differential risks on metabolic side-effects amongst these SGAs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Antipsychotics and Blood Vessel Function

NCT00585273

Bipolar Disorder Schizophrenia

COMPLETED

Metabolic Effects of Melatonin in Patients Treated With Second Generation Antipsychotics

NCT01811160

Second Generation Antipsychotic Induced Metabolic Adverse Effects

COMPLETED PHASE4

Effects of Adjunctive Metformin on Metabolic Profiles in Clozapine-treated Schizophrenic Patients

NCT01300637

Obesity Metabolic Syndrome Schizophrenia

UNKNOWN NA

Alleviating the Metabolic Side Effects of Antipsychotic Medications

NCT01567124

Schizophrenia

WITHDRAWN PHASE4

Glucose and Lipid Metabolism on Antipsychotic Medication

NCT00515723

Schizophrenia Schizoaffective Disorder Type 2 Diabetes Mellitus +1 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mental Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SGAs

patients receiving SGAs

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* was ≥18 years of age
* out-patients
* had received any one of these antipsychotics: aripiprazole, amisulpride, clozapine, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone
* consented to provide physical measurements and venous blood samples